MiNK Therapeutics To Present New Data At ASGCT 2026 Showing iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS

MiNK Therapeutics, Inc. +2.87% Pre

MiNK Therapeutics, Inc.

INKT

11.47

11.47

+2.87%

0.00% Pre

Presentation Details:

  • Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS
  • Presenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK Therapeutics
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.